Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MZT2B CRISPR/Cas9 KO Plasmid (h): sc-406507
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MZT2B CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MZT2B genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MZT2B CRISPR/Cas9 KO Plasmid (h) | sc-406507 | 20 µg | $397.00 |
Overview
MZT2B (mitotic spindle organizing protein 2B) encodes a small centrosomal protein that participates in microtubule organization through the γ-tubulin ring complex (γTuRC) and associated factors at the centrosome. By supporting γ-tubulin–dependent microtubule nucleation, MZT2B contributes to spindle assembly, centrosome function, and faithful chromosome segregation during mitosis. Disruption of centrosome and spindle regulatory networks is a common feature of genome instability, linking MZT2B-related pathways to cell-cycle dysregulation frequently studied in cancer biology and proliferative stress models. MZT2B is therefore relevant for investigating centrosome homeostasis, mitotic progression, and microtubule-dependent trafficking processes.
MZT2B CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MZT2B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MZT2B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MZT2B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MZT2B protein expression.
This CRISPR knockout system enables efficient generation of MZT2B-deficient cell models for investigation of MZT2B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MZT2B exon(s) critical for MZT2B function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MZT2B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MZT2B CRISPR/Cas9 KO Plasmid (h) and MZT2B CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MZT2B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MZT2B HDR Plasmid (h) and MZT2B HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MZT2B homology arms to support homology-directed repair at defined MZT2B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.